2018-02-27 · The Journal needs to be relevant to the broad church of toxicology. I am very keen to encourage themed issues to help those new to the field identify Toxicology Research as source of up to date information . Once again, we’d like to congratulate Heather on her new role and we look forward to her term as editor-in-chief.

2021-04-15 · Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents. Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor.

Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). 2020-12-23 · Expert Review of Anticancer Therapy Provides expert appraisal in cancer care, including tumor management, novel therapies, anticancer agents, chemotherapy, cancer vaccines, and biomarkers. Search in: This Journal Anywhere Dr. Pham joined Cell Press in 2008 as a member of the Molecular Cell editorial team and became the journal’s Editor-in-Chief in 2012. In this role, he has expanded his scientific expertise across the broad range of areas that Molecular Cell covers and has led initiatives on transparency and integrity, piloted new policies on data archiving, and tested different approaches to peer review. EDITOR-IN-CHIEF Matthew Ringel MD, PhD Ralph W. Kurtz Professor of Medicine, and Director of the Division of Endocrinology and Metabolism at The Ohio State University, OH, USA Dr Ringel is the Co-Director of the Center for Cancer Engineering and Co-Leader of the Cancer Biology at Ohio State Comprehensive Cancer Center. This section on Pharmacology of Anti-Cancer Drugs is devoted to the publication of high quality research concerning all aspects of cancer and benign neoplasm drug treatment. The scope of the specialty section encompasses studies related to drugs targeting tumor cells, but also the various components of the tumor microenvironment, including non-tumor cells (e.g., endothelial cells, macrophages Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target.

Anticancer research editor in chief

He has authored numerous scientific articles, books, and book chapters. His present interests include: development of anticancer drugs, intraperitoneal therapy for gynecologic and gastrointestinal cancers, and early identification and prevention of cancers in women at high-risk. Associate Editor-in-Chief Terms of Appointment: May 2019 – Apr 2024 Editor-in-Chief Shana Sturla Institute of Food, Nutrition, and Health Department of Health Sciences and Technology ETH Zurich Schmelzbergstrasse 9 8092 Zurich Switzerland E-mail: [email protected] Selected Honors and Accolades. American Chemical Society Chemical Research in Toxicology Young Investigator Award My task is to effect US, CEUS, TC and MRI, more specifically abdominal radiology and musle-skeleltal radiology.

In Vivo. Cancer Genomics & Proteomics. Submit your manuscript.

1981年に International Institute of Anticancer Research （英語版）の機関誌としてJohn G. Delinasios（現在も編集長）によって創刊された。. 当初は隔月刊誌であったが、2009年から月刊誌となっており、現在は HighWire Press （英語版） (USA) から印刷物とオンラインで公開されている。. 論文の迅速な評価と採択後1-2ヶ月以内の迅速な出版を目標としている。.

This section on Pharmacology of Anti-Cancer Drugs is devoted to the publication of high quality research concerning all aspects of cancer and benign neoplasm drug treatment. The scope of the specialty section encompasses studies related to drugs targeting tumor cells, but also the various components of the tumor microenvironment, including non-tumor cells (e.g., endothelial cells, macrophages Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target.

Editor-in-Chief Shana Sturla Institute of Food, Nutrition, and Health Department of Health Sciences and Technology ETH Zurich Schmelzbergstrasse 9 8092 Zurich Switzerland E-mail: [email protected] Selected Honors and Accolades. American Chemical Society Chemical Research …

Michelle Prudhomme was the founding Editor (2000) and is currently the Editor-in-Chief of this journal (Anti-Cancer Agents in Medicinal Chemistry), published by Bentham Science Publishers. Close Associate Editors Editorial Office in U.S.A.: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA. E-mails: Editorial Office: journals@iiar-anticancer.org. Managing Editor: editor@iiar-anticancer.org. Galley Proofs. Galley proofs will be sent by e-mail to the corresponding Author.

214662, is on e of t he recent non-peptide imidazole . FTi showing high affini ty for FTase over GGTase . LetPub Scientific Journal Selector (2018-2021), ANTICANCER RESEARCH published in 1981, GREECE. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Proppar handen

Galley Proofs. Galley proofs will be sent by e-mail to the corresponding Author.

An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs Vinks AA, Derendorf H, Mouton JW. editors. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York, USA: Springer, 2014.
Arrogant bastard aurora

My task is to effect US, CEUS, TC and MRI, more specifically abdominal radiology and musle-skeleltal radiology. I have published till now 133 reports in the most important medical journal of the sector ( Radiology, AJR, BJR, Eur Radiol, Radiol Medi, Ann of Hepatology, Anticancer Research, Updates in …

According to the Journal Citation Reports, the journal had a 2016 impact factor of 1.937 and 18,614 total cites. The impact factor for 2019 was 1.994 and the 2020 rejection rate was 68%. Jonathan W. Friedberg, MD, MMSc, has been appointed as the next editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO). JCO publishes cutting-edge research on the diagnosis and treatment of patients with cancer and is one of the most highly cited oncology journals in the world. Some of his research work was awarded the First Prize of Scientific and Technology Progress.